メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
松岡 賢市
医学部
准教授
,
大学院医歯薬学総合研究科
准教授
,
医歯薬学域
h-index
3080
被引用数
21
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2004
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(160)
類似のプロファイル
(6)
フィンガープリント
Ken-ichi Matsuokaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Immunology and Microbiology
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Transplant Procedure
80%
Hematopoietic Cell
75%
Cell Transplantation
75%
Graft-Versus-Host Disease
72%
Overall Survival
67%
Cyclophosphamide
54%
Chronic Graft Versus Host Disease
49%
Hematopoietic Stem Cell Transplantation
48%
Regulatory T Cell
46%
Myeloid
36%
Conditioning
36%
T Cell
35%
Low Drug Dose
34%
Stem Cell Transplantation
26%
Peripheral Blood Stem Cell
26%
Homeostasis
26%
Acute Graft Versus Host Disease
25%
Interleukin 2
21%
Cytomegalovirus
20%
Anti-Thymocyte Globulin
20%
Peripheral Blood Stem Cell Transplantation
18%
Lymphocyte
15%
Human Leukocyte Antigen
15%
Progression Free Survival
14%
Allogeneic Stem Cell Transplantation
14%
B Cell
13%
Survival Rate
13%
Engraftment
12%
Recurrence Free Survival
12%
Programmed Cell Death 1
12%
Influenza
12%
Neutrophil
11%
CD4
11%
Cord Blood Stem Cell Transplantation
10%
Comorbidity
9%
Platelet
9%
Lymphocytopenia
9%
Umbilical Cord Blood
8%
Allotransplantation
8%
Rituximab
8%
Mogamulizumab
8%
Leukapheresis
8%
Lung Transplantation
8%
Aplastic Anemia
8%
Cytokine Release Syndrome
8%
Chimeric Antigen Receptor T-Cell Therapy
8%
T-Helper Cell
7%
CD34
7%
Mouse
7%
Medicine and Dentistry
Allogeneic Hematopoietic Stem Cell Transplantation
68%
Cell Transplantation
53%
Hematopoietic Stem Cell
53%
Hematopoietic Stem Cell Transplantation
36%
Acute Myeloid Leukemia
36%
Myelodysplastic Syndrome
36%
Overall Survival
32%
Transplantation
24%
Hazard Ratio
20%
Diffuse Large B-Cell Lymphoma
18%
Peripheral Blood Stem Cell
17%
Graft Versus Host Reaction
17%
Cell Therapy
16%
Neoplasm
15%
Fludarabine
15%
Retrospective Study
14%
Busulfan
13%
Allogeneic Stem Cell Transplantation
13%
Stem Cell Therapy
12%
Conditioning
12%
Chronic Graft Versus Host Disease
12%
Disease
11%
Influenza
11%
Acute Graft Versus Host Disease
11%
Adult T-Cell Leukemia/Lymphoma
11%
Cord Blood
10%
Multivariate Analysis
10%
Cytomegalovirus
9%
Cumulative Incidence
9%
Reduced Intensity Conditioning
9%
Cyclophosphamide
9%
Donor Lymphocyte Infusion
8%
Myeloablative Conditioning
8%
Prognostic Factor
8%
Graft Failure
8%
Wilms' Tumor
8%
MALT Lymphoma
8%
Azacitidine
8%
Photodynamic Therapy
8%
Leukapheresis
8%
Aplastic Anemia
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
8%
Peripheral Blood Stem Cell Transplantation
7%
Recurrence Free Survival
7%
Leukemia
7%
B Cell
6%
Patient with Non-Hodgkins Lymphoma
6%
Myelodysplastic Syndrome
6%
Hematologic Malignancy
6%
Allele
6%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
69%
Graft-versus-host Disease (GvHD)
30%
Hazard Ratio
21%
Post-transplantation Cyclophosphamide (PTCy)
21%
Myelodysplastic Syndrome
18%
Unrelated Donor
15%
Hematopoietic Stem Cell Transplantation
15%
Japan
14%
HLA-haploidentical
12%
Haploidentical Transplantation
12%
Non-infectious Pulmonary Complication
12%
Reduced-intensity Conditioning
12%
Confidence Interval
11%
Non-relapse Mortality
11%
Bone Marrow
10%
Retrospective Analysis
10%
HLA-matched Donor
9%
Antithymocyte Globulin
9%
Diffuse Large B-cell Lymphoma (DLBCL)
9%
Peripheral Blood Stem Cells
8%
Donor Source
8%
Transplant Complications
8%
Virus Infection
8%
Epstein-Barr Virus
8%
Haploidentical Peripheral Blood Stem Cell Transplantation
8%
Busulfan
8%
Fludarabine
8%
Letermovir
8%
Treg
7%
Overall Survival
7%
Transplant Outcomes
7%
Myeloablative Conditioning
7%
Haploidentical Donor
6%
Peripheral Blood
6%
Graft-versus-host Disease Prophylaxis
6%
Acute Myeloid Leukemia
6%
Adult Patients
6%
Transformed Diffuse Large B Cell Lymphoma
6%
Peripheral Blood Stem Cell Transplantation
6%
Low-dose interleukin-2
6%
Transplant Registry
5%
Registry Data
5%
Transplantation
5%
Conditioning Regimen
5%
Dendritic Cells
5%
Regulatory T Cells
5%
Treg Homeostasis
5%
Management Program
5%
Donor Type
5%
